FDA Establishes Regulatory Review Period for Rytelo
February 13, 2026
February 13, 2026
WASHINGTON, Feb. 13 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration announced the determination of the regulatory review period for the human drug product Rytelo. This notice follows applications submitted by Geron Corp., Foster City, California, to the U.S. Department of Commerce Patent and Trademark Office for the extension of several patents.
Rytelo, known chemically as imetelstat, is indicated for treating adult patients with specific typ . . .
Rytelo, known chemically as imetelstat, is indicated for treating adult patients with specific typ . . .